TOP > 外国特許検索 > MAINTENANCE CULTURE OF INTESTINAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS

MAINTENANCE CULTURE OF INTESTINAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS NEW

外国特許コード F180009548
整理番号 (S2017-0284-N0)
掲載日 2018年11月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP005849
国際公開番号 WO 2018151307
国際出願日 平成30年2月20日(2018.2.20)
国際公開日 平成30年8月23日(2018.8.23)
優先権データ
  • 特願2017-029448 (2017.2.20) JP
発明の名称 (英語) MAINTENANCE CULTURE OF INTESTINAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS NEW
発明の概要(英語) The present invention addresses the problem of providing a culture method with which it is possible to maintain and culture intestinal stem cells derived from induced pluripotent stem cells while maintaining the properties of the intestinal stem cells. Intestinal stem cells derived from induced pluripotent stem cells are cultured in the presence of a GSK-3β inhibitor, a histone deacetylation inhibitor, and a serum substitute, or in the presence of a GSK-3β inhibitor and a serum substitute. Preferably, the cells are cultured under conditions such that one or more compounds selected from the group consisting of epidermal growth factors, TGFβ receptor inhibitors, and fibroblast growth factors are also present.
従来技術、競合技術の概要(英語) BACKGROUND ART
The drug-metabolizing enzyme and a number of the small intestine is present in the drug transporter, similar to the liver, according to the first-pass effect of the drug as an organ is very important.Therefore, the small intestine from the early stages of drug development of pharmaceuticals in the membrane permeability of the evaluation and metabolism, pharmacokinetic properties required for the development of pharmaceutical products is excellent.The current, derived from the small intestine of the human colon cancer is as a model system is widely used in the Caco-2 cells.However, drug transporter Caco-2 cells is different from the expression patterns of human small intestine.In addition, the drug-metabolizing enzyme in the Caco-2 cell expression and enzyme induction is not found substantially, accurately evaluate the pharmacokinetics of the small intestine is difficult.Therefore, in the small intestine and the membrane permeability in drug metabolism for comprehensively evaluating the use of the small intestine epithelial cells is desirable that the primary, it is difficult to obtain primary small intestine epithelial cells.
Therefore, human embryonic stem cell (embryonic stem cells: ES cells) in the same manner as the growth of an almost infinite and multipotent and pluripotent stem cells have the ability to human artificial (induced pluripotent stem cells: cell iPS) cells of the intestinal epithelium made is expected to be used.
Incidentally, in the gastrointestinal tract from the intestinal tract of a living organism isolated stem cells, intestinal epithelial cells in vitro culturing the stem cells of the intestinal tract or iPS cells and a technique to induce the differentiation of human intestinal epithelial cells from the technology has been reported that some (for example JP-1-4, see Non-Patent Document 1-3), human iPS cells from stem cell maintenance or growth in the gastrointestinal tract for the purpose has not been reported in culture techniques.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY
  • 発明者(英語)
  • Yuhiro Iwao
  • Toshihide Matsunaga
  • Satoshi Kondo
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close